newsfilter
← Latest News
GlobeNewswire·

Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody

Novel dual-mechanism anti-IgE antibody designed to improve upon existing and emerging therapies for IgE-mediated diseases Cue Biopharma plans to initiate global Phase 2b trial in food allergy following anticipated